1. Home
  2. VALN vs MTLS Comparison

VALN vs MTLS Comparison

Compare VALN & MTLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VALN
  • MTLS
  • Stock Information
  • Founded
  • VALN 2012
  • MTLS 1990
  • Country
  • VALN France
  • MTLS Belgium
  • Employees
  • VALN N/A
  • MTLS N/A
  • Industry
  • VALN Biotechnology: Biological Products (No Diagnostic Substances)
  • MTLS Computer Software: Prepackaged Software
  • Sector
  • VALN Health Care
  • MTLS Technology
  • Exchange
  • VALN Nasdaq
  • MTLS Nasdaq
  • Market Cap
  • VALN 488.9M
  • MTLS 418.2M
  • IPO Year
  • VALN 2021
  • MTLS 2014
  • Fundamental
  • Price
  • VALN $4.66
  • MTLS $6.89
  • Analyst Decision
  • VALN Strong Buy
  • MTLS Buy
  • Analyst Count
  • VALN 2
  • MTLS 1
  • Target Price
  • VALN $18.50
  • MTLS $9.50
  • AVG Volume (30 Days)
  • VALN 22.7K
  • MTLS 251.7K
  • Earning Date
  • VALN 11-07-2024
  • MTLS 10-24-2024
  • Dividend Yield
  • VALN N/A
  • MTLS N/A
  • EPS Growth
  • VALN N/A
  • MTLS 323.01
  • EPS
  • VALN N/A
  • MTLS 0.19
  • Revenue
  • VALN $176,817,979.00
  • MTLS $297,100,156.00
  • Revenue This Year
  • VALN $24.30
  • MTLS $7.93
  • Revenue Next Year
  • VALN $16.05
  • MTLS $10.21
  • P/E Ratio
  • VALN N/A
  • MTLS $36.52
  • Revenue Growth
  • VALN N/A
  • MTLS 5.07
  • 52 Week Low
  • VALN $4.60
  • MTLS $4.70
  • 52 Week High
  • VALN $12.85
  • MTLS $7.56
  • Technical
  • Relative Strength Index (RSI)
  • VALN 26.32
  • MTLS 62.91
  • Support Level
  • VALN $4.63
  • MTLS $6.02
  • Resistance Level
  • VALN $5.28
  • MTLS $7.56
  • Average True Range (ATR)
  • VALN 0.18
  • MTLS 0.34
  • MACD
  • VALN -0.09
  • MTLS 0.08
  • Stochastic Oscillator
  • VALN 4.05
  • MTLS 60.82

About VALN Valneva SE

Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates the majority of its revenue from product sales.

About MTLS Materialise NV

Materialise NV is a provider of 3D printing services. The products and services of the group are organized in three segments: Medical segment, which develops and delivers medical software solutions, medical devices, and other related products and services; Software segment, which develops and delivers additive manufacturing software solutions and related services; and Manufacturing segment, which delivers 3D printed products and related services. Its geographical segments are the United States, the Americas (excluding the USA), Belgium, Germany, Poland, France, Switzerland, the United Kingdom, Italy, the Netherlands, Other Europe, and the Asia Pacific.

Share on Social Networks: